Previous 10 | Next 10 |
The following slide deck was published by AVROBIO, Inc. in conjunction with this Read more ...
AVROBIO (NASDAQ: AVRO ) : Q2 GAAP EPS of -$0.80 misses by $0.02 . More news on: AVROBIO, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
New data indicate stable kidney function across the two Fabry disease clinical studies up to 32 months New six-month Phase 2 FAB-201 data from first patient treated using AVROBIO’s plato ® gene therapy platform show continued reduction in toxic metabolite plasma lyso-Gb3 a...
AVROBIO, Inc . (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference at 1:10 p.m. ET on ...
Avrobio (NASDAQ: AVRO ) doses first patient in its Phase 1/2 GuardOne clinical trial , evaluating AVR-RD-02 for Gaucher disease type 1, an inherited disorder caused by the accumulation of a type of lipid in tissues due to the dysfunction in a certain enzyme. More news on: AVRO...
First patient dosed in AVROBIO’s global Phase 1/2 clinical trial of AVR-RD-02 for Gaucher disease type 1 Second patient dosed in investigator-sponsored Phase 1/2 clinical trial of AVR-RD-04 for cystinosis AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene ther...
AVROBIO co-founder and veteran gene and cell therapy pioneer Kim Warren to retire July 31, 2020 AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Kim Raineri...
The following slide deck was published by AVROBIO, Inc. in conjunction with this Read more ...
AVROBIO’s optimized lentiviral vectors demonstrate significant glycogen reduction in the muscle and central nervous system of Pompe disease mouse model Investigational New Drug (IND)-enabling proof-of-concept study for AVR-RD-03 for Pompe disease currently underway AVROBI...
Thinly traded AVROBIO (NASDAQ: AVRO ) jumps 4% premarket on light volume in reaction to updated data from a Phase 2 study evaluating its AVR-RD-01 gene therapy in patients with Fabry disease , an inherited disorder characterized by the buildup of a type of fat in the bo...
News, Short Squeeze, Breakout and More Instantly...
2024-06-20 09:02:05 ET AvroBio Inc (AVRO) announced stock split at a ratio of 1-for-12 on 2024-06-21 ... Full story available on KlickAnalytics.com
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...